News | February 08, 2011

FDA Approves NDA for Sodium Fluoride F18 Injection

February 9, 2011 – In an announcement by the National Cancer Institute (NCI) and the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for use of a new strength of a previously approved drug, sodium fluoride F 18 (18F-NaF) injection, for use in bone scans.

PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA Inc., is the only commercial manufacturer to be included in this NDA for 18F-NaF injection, at this time.

For more information: www.siemens.com/healthcare

Related Content

Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning.

Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning. (Images courtesy of Metrasens)

Feature | Magnetic Resonance Imaging (MRI) | July 03, 2018 | By Tobias Gilk
Nearly every job in the country is subject to certain health and safety regulations. Construction workers must wear...
Carestream DRX-Revolution Nano Mobile X-ray System

The Carestream DRX-Revolution Nano Mobile X-ray System.

Feature | Digital Radiography (DR) | July 03, 2018 | By Melinda Taschetta-Millane
The mobile digital radiography (DR) segment is the largest segment by product type in the global digital mobile DR...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
Overlay Init